These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32043089)

  • 1. Current Methods for Quantifying Drug Synergism.
    Ma J; Motsinger-Reif A
    Proteom Bioinform; 2019 Jul; 1(2):43-48. PubMed ID: 32043089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is synergy? The Saariselkä agreement revisited.
    Tang J; Wennerberg K; Aittokallio T
    Front Pharmacol; 2015; 6():181. PubMed ID: 26388771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
    Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
    Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of synergism in drug combinations and reference models for future orientations in oncology.
    Duarte D; Vale N
    Curr Res Pharmacol Drug Discov; 2022; 3():100110. PubMed ID: 35620200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.
    Roell KR; Reif DM; Motsinger-Reif AA
    Front Pharmacol; 2017; 8():158. PubMed ID: 28473769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures.
    Schindler M
    Theor Biol Med Model; 2017 Aug; 14(1):15. PubMed ID: 28768512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive Dose Response Models: Defining Synergy.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2019; 10():1384. PubMed ID: 31849651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interaction: focusing on response surface models.
    Lee SI
    Korean J Anesthesiol; 2010 May; 58(5):421-34. PubMed ID: 20532049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fitting models for the joint action of two drugs using SAS.
    Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK
    Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical formulation of additivity for antimicrobial agents.
    Boucher AN; Tam VH
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):319-25. PubMed ID: 16626903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Charting the Fragmented Landscape of Drug Synergy.
    Meyer CT; Wooten DJ; Lopez CF; Quaranta V
    Trends Pharmacol Sci; 2020 Apr; 41(4):266-280. PubMed ID: 32113653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.
    Goldoni M; Johansson C
    Toxicol In Vitro; 2007 Aug; 21(5):759-69. PubMed ID: 17420112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Effect of Mycotoxin Combinations: Which Mathematical Model Is (the Most) Appropriate?
    Kifer D; Jakšić D; Šegvić Klarić M
    Toxins (Basel); 2020 Feb; 12(3):. PubMed ID: 32121330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additivity of inhibitory effects in multidrug combinations.
    Russ D; Kishony R
    Nat Microbiol; 2018 Dec; 3(12):1339-1345. PubMed ID: 30323252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
    Meletiadis J; Verweij PE; TeDorsthorst DT; Meis JF; Mouton JW
    Med Mycol; 2005 Mar; 43(2):133-52. PubMed ID: 15832557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
    Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG
    Mol Cancer Ther; 2014 Jul; 13(7):1964-76. PubMed ID: 24755197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.
    Tam VH; Schilling AN; Lewis RE; Melnick DA; Boucher AN
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4315-21. PubMed ID: 15504858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple test for synergy for a small number of combinations.
    Novick SJ
    Stat Med; 2013 Dec; 32(29):5145-55. PubMed ID: 23904140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.